Nano-Ditech Corporation, founded in 2002, is a biotech company specializing in the development and manufacture of high tech immuno-diagnostic products for the medical and research laboratory markets. Nano-Ditech targets a fast growing Point of Care (POC) in-vitro diagnosis (IVD) market with innovations in rapid assay techniques including microfluidics technologies for Electro- Immuno chromatography lab on a film chip (EI LOFC). The Nano-Ditech scientific and marketing staff have extensive experience in the IVD industry and are able to utilize this expertise to develop and successfully market new diagnostic products. . Nano-Ditech has developed numerous forensic and diagnostic test devices based on immuno-chromatograpy assays for human and animal health. Recently, Nano-Ditech received FDA 510K clearance and CE mark for some of its products, Nano-Check TM DAT 5 for Drugs of Abuse Test and Nano-Check TM AMI 3in1 for Acute Myocardial Infarction Test. Head offices are located at central New Jersey, USA with 5000sft of Lab and office space in research incubation complex. The key technology of Nano-Ditech is Lab On a Film Chip, which has passed the feasibility test recently and in processing of patent (US60/410312). The LOFC will provide a new plat-form technology in point of care (POC) in-vitro diagnostic (IVD) industry. LOFC is a disposable microfluidics diagnostic chip for qualitative and quantitative immunoassays. This new diagnostic device is applicable to all kinds of immunoassay used today. But the main objective is integration in the Point of Care market, including home diagnostic products, which are currently occupied by membrane based immuno-chromatography assay tests. With our expertise and related intellectual properties, Nano-Ditech will become the leading company in the immuno-diagnostic industry.
CMDX is a wholly owned subsidiary of CombiMatrix Corporation (Nasdaq:CBMX;ACTG), a biotechnology company headquartered near Seattle, Washington, USA. CMDX's first cancer diagnostic products, utilizing CombiMatrix's patented CustomArrayÔ technology, will be available via our clinical diagnostics laboratory.
Cellestis Limited is an Australia-based company that is principally engaged in the developing, manufacturing and marketing of medical diagnostic products. The Company commercialises and develops QuantiFERON technology (QFT) worldwide. It operates in three principal areas: Australia (including Japan), the United States and Europe. The Company’s core business functions (marketing, research and development, manufacturing and finance) are located in Australia, with sales, marketing and distribution also operating in the United States and Europe (Germany). The Company’s wholly owned subsidiaries include Cellestis Inc, Cellestis International Pty Ltd, Cellestis (R&D) Pty Ltd, Cellestis GmbH and Cellestis Asia Kabushiki Kaisha. (Source: ARS)
Banyan Biomarkers is the leader in developing in vitro diagnostic products to address unmet clinical needs for the detection of traumatic brain injury (TBI). Currently, no simple point-of-care blood test exists for use by physicians in the emergency room or in the hospital to detect the presence and severity of brain trauma. Banyan research has identified unique and proprietary biomarkers present in the patient's blood following injury to the brain. Detecting these biomarkers will provide early indications of brain trauma essential for earlier intervention and management.
T2 Biosystems is a private biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MRI) technology to provide rapid, accurate and portable diagnostics. T2 Biosystems was founded in 2006 by renowned researchers from the Massachusetts Institute of Technology, Harvard University, Harvard Medical School and Massachusetts General Hospital, and has assembled a world-class team, board of directors and scientific advisory board that collectively have a proven track record of translating technologic innovations into breakthrough products, building significant corporate value. T2 Biosystems is located in Cambridge, Massachusetts.
http://www.ostabiotechnologies.com
Osta Biotechnologies Inc. is a biopharmaceutical company whose principal business is to carry out research and development work for the development of diagnostic and therapeutic products for Alzheimer's disease, X-Linked Hypophosphatemic rickets, osteoporosis and osteoarthritis. As of December 31, 2007, the Company’s products and technologies were in the research and developmental stage, and it had not generated any revenues from sales. (Source: ARS)
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the Company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic agent in chronic kidney disease patients. The Company submitted a New Drug Application for marketing approval of ferumoxytol with the U.S. Food and Drug Administration (FDA) in December 2007, which was accepted for filing by the FDA in February 2008.
Cedarlane Laboratories Limited is an ISO 9001 and ISO 13485 certified privately held Canadian corporation. Cedarlane has been in business since 1957. It was incorporated in 1975 by three Canadian researchers originating from the University of Toronto and Ontario Cancer Institute; Dr. S. Abrahams, Dr. A.J. Farmilo and R.C. Course. The company has evolved to become a leading supplier of research reagents in Canada and world-wide, particularly in the area of immunology. It is located in Burlington, Ontario, Canada with close proximity to Pearson International Airport and the Toronto area. Cedarlane is both a manufacturer and distributor. Manufactured products include monoclonal antibodies, polyclonal antibodies, cell separation media, complement for tissue typing, and immunocolumns. These are available world-wide through a well-established network of international distributors. Products distributed within Canada are imported from over 500 international suppliers and are offered to our Canadian customer base of ~ 20,000 life science researchers. Cedarlane Shipping Supplies Inc. is a daughter company established ~ 5 years ago and specializes in providing shipping supplies for temperature-sensitive goods.
Based in Dallas, Texas, Cytoclonal was founded in 1991 by Dr. Arthur P. Bollon who serves as Founder and Vice Chairman since December, 2000 and was Chairman since the Company's inception in 1991 to December, 2000 and President and Chief Executive Officer since the Company's inception in 1991 to March, 2001. In 1995, Cytoclonal completed an initial public offering raising $11.5 million. In year 2000 the Company raised $37.5 million from the conversion of C and D warrants. The company occupies 24,100 square feet of office and laboratory space.
PROTOMETRIX, Inc. is a biotechnology company dedicated to the development and application of proprietary integrated proteomics technologies to improve human health. The company began formal operations in May 2001 and currently occupies a state-of-the-art facility in Branford, CT. Its technologies are based on the pioneering protein microarray work of Professor Michael Snyder of Yale University. The core capabilities of the company include both production and investigation of the function and interaction of thousands of proteins in parallel using nanoscale technology and collection of all of the information in a state-of-the-art informatics database. In addition, this database is a valuable predictor that provides direction in experimental design. Its technology allows definition and study of proteomes (the comprehensive complement of proteins produced by an organism) of any species for the first time.
Monogram Biosciences, Inc. (Monogram) is a life sciences company committed to advancing personalized medicine and improving patient outcomes through the development of molecular diagnostic products that guide and target the appropriate treatments. Through an understanding of the genetics, biology and pathology of particular diseases, the Company is developing molecular diagnostics and laboratory services that are designed to enable physicians to manage infectious diseases and cancers by providing the critical information that helps them prescribe personalized treatments for patients by matching the underlying molecular features of an individual patient’s disease to the drug expected to have maximal therapeutic benefit, and enable pharmaceutical companies to develop new and improved anti-viral therapeutics and targeted cancer therapeutics by providing enhanced patient selection and monitoring capabilities throughout the development process. (Source: 10-K)
ZymeTx, Inc. is a biotechnology company engaged in the development, distribution and introduction of novel solutions for the diagnosis, treatment and surveillance of infectious viral diseases. These products include the ZstatFlu® Rapid Test for Influenza A and B, ViraStat® Parainfluenza Laboratory Test, and the National Flu Surveillance Network - NFSN®.
ChondroGene Limited is a molecular diagnostics company that is developing proprietary blood-based molecular diagnostic tests for diseases with unmet clinical needs and significant commercial opportunities. The tests are based on the Company's breakthrough Sentinel Principle and are being developed in the areas of cancer, central nervous system disorders, cardiovascular diseases and arthritis with the initial focus for commercialization in cancer. To develop these tests, ChondroGene is applying the Sentinel Principle to generate molecular signatures from blood. These molecular signatures are used to identify disease-specific biomarkers which are the foundation for ChondroGene's highly sensitive and specific molecular diagnostic assays. ChondroGene is able to generate specific biomarkers in different disease areas for numerous applications including: Predicting disease risk Early diagnosis Determining stage of disease Identifying responders/non-responders to a specific therapy Monitoring progression/recurrence of disease Monitoring the effects of treatment Monitoring treatment compliance The broad applicability of the Sentinel Principle across a wide range of diseases and its ability to address a diverse spectrum of specific clinical questions means that it is truly a breakthrough technology with the ability to enable Personalized Health Management.
Perlegen was founded in 2001 as a spin-out from Affymetrix, a genetic tools company. For the first several years of its existence, until about 2004, Perlegen was focused on re-sequencing 50 human genomes, in order to map out the common elements of genetic diversity. During this time, Perlegen developed a majority of the content now publicly available in the "HapMap," or human haplotype map.
Bionomics Limited is engaged in research and development utilizing Bionomics’ technology platforms with the focus of identifying and developing therapies to treat cancer and conditions of the Central Nervous System (CNS), including anxiety multiple sclerosis and epilepsy. The Company is also engaged in commercializing intellectual property assets, and identifying alliances and project opportunities. It discovers and develops therapeutics in the areas of cancer, multiple sclerosis, anxiety and epilepsy. It operates in a single business segment: drug discovery and development. (Source: ARS)
CombiMatrix Corporation, formerly Acacia Research-CombiMatrix, is a biotechnology company, with a subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX). CombiMatrix's electrochemical manufacturing process utilizes standard semiconductor technology, software and chemistry to build arrays of materials. The Company's CustomArray products are deoxyribonucleic acid (DNA) microarrays, which have uses in pharmaceutical, biotech and agrochemical industries, as well as in research and government markets. The Company also uses its technology in synergistic internal programs for diagnostics development, drug development, and biodefense in addition to partnerships for nanomaterials development.
Cylex Incorporated® (Cylex) is a global life science company that develops and manufactures research and in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow® is an in vitro diagnostic utilized to detect cell mediated immunity in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the country. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure immune cell function for the development of new diagnostics, biomarkers and companion assays.
Innogenetics is an international biopharmaceutical company building parallel businesses in the areas of specialty diagnostics and therapeutic vaccines. In 2004, total revenues reached euro 71 million, with a profitable Diagnostics Division. Its Diagnostics Division develops a large number of specialty products covering three areas: infectious diseases (hepatitis C, hepatitis B, and HIV), genetic testing (HLA tissue typing and cystic fibrosis), and neurodegeneration (Alzheimer's disease). In its Therapeutics Division, Innogenetics focuses on the development of therapeutic vaccines to address unmet medical needs in the field of infectious diseases, with two compounds now in clinical trials (hepatitis C in phase II and hepatitis B in phase I). Founded in 1985, Innogenetics is listed on Euronext Brussels.
IBEX Technologies, Inc. (IBEX) is a biopharmaceutical company engaged in the production and sale of enzymes for use as reagents in hemostasis monitoring devices, and of arthritis diagnostic kits for pharmaceutical research. It is principally engaged in the production and sale of diagnostic products. IBEX sells its products, enzymes and diagnostic kits, either directly or through distributors. It has focused on the isolation, characterization and high-level expression of glycosaminoglycan GAG lyase enzymes derived from Flavobacterium heparinum, a non-pathogenic soil organism. IBEX has developed a Flavobacterium heparinum production system. This system allows the production of recombinant forms of these GAG lyases. IBEX produces heparinase I, heparinase II, heparinase III, chondroitinase AC and chondroitinase B. (Source: ARS)
Hawaii Biotech, Inc. (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. We have developed a proprietary protein production platform that is applicable to the production of vaccine antigens. Our lead vaccine candidates target the West Nile virus and the viruses responsible for seasonal influenza. A dengue vaccine is also under development for individuals traveling to or living in dengue endemic areas. HBI has built a management team with relevant experience at companies such as Lederle, GlaxoSmithKline, QED Technologies, Syngenta, Chiron and Viagene. Collaborators, past and present, include scientists from Harvard Medical School; the University of Texas Medical Branch, Galveston; the University of Hawaii; the Walter Reed Army Institute of Research; the U.S. Army Medical Research Institute for Infectious Disease (USAMRIID); the Southwest Foundation for Biomedical Research; and the Centers for Disease Control and Prevention.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory